We also found that MUC1-C induces (i) PLK1, which is dysregulated in SCLC and is a target for SCLC treatment (41) and (ii) aurora kinase A, which has been targeted in MYC amplified SCLC cells with alisertib and other aurora kinase inhibitors (Fig. 7F; ref. 5). Here, PLK1 is linked to small cell lung carcinoma.